Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in
combination with palbociclib and fulvestrant compared with placebo plus palbociclib and
fulvestrant in participants with PIK3CA-mutant, hormone receptor (HR)-positive,
HER2-negative locally advanced or metastatic breast cancer whose disease progressed
during treatment or within 12 months of completing adjuvant endocrine therapy and who
have not received prior systemic therapy for metastatic disease.